Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$4.11 - $28.68
Next Earnings Date
May 12 2025
Next Earnings Date
May 12 2025
Last Price
Market Cap | $48.33M |
EV | $-10.04M |
Shares Outstanding | 6.58M |
Beta | 2.86 |
Analyst Rating | BUY |
Analyst Target Price | $59.00 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | 32.10% |
Operating Cash Flow | -22.60% |
Free Cash Flow | -21.40% |
Revenue | - |
EPS | 52.90% |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -80.82% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Forte Biosciences, Inc.
FBRX
Sector
Healthcare
Industry
Biotechnology
CEO
Wagner, Paul A.
Employees
14
Website
www.fortebiorx.comIPO Date
2017-04-13
Headquarters
3060 Pegasus Park Drive, Building 6, Dallas, Texas, 75247, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved